Mindstate Design Labs
Phase I1 active candidate
same indication: Major Depressive Disorder (MDD)Phase I peersame regulator: EU EMAsimilar active pipeline size
Back to StakeholdersProgramme tracker View landscape
Lead program: Phase I
Categories
1 domain / 2 areas / 1 specialization
Lophora
Also known as: Lophora ApS
Data updated
2 Drug Candidates
Lophora ApS is a Danish biotech developing next-generation selective 5-HT2A receptor agonists for psychiatric disorders. Their lead compound LPH-5, a novel cyclized phenethylamine, is in Phase 1 trials at Biotrial in Rennes, France. LPH-5 shows exceptional 5-HT2A selectivity and can produce antidepressant effects at sub-psychedelic doses. Secondary candidate LPH-48 is being explored for alcohol use disorder.
Pipeline Intelligence
Developer Momentum
- Active candidates
- 2
- Active programmes
- 2
- Lead stage
- Phase I
- Forecast coverage
- 2 of 2
All tracked candidates active
All tracked programmes active
Multiple active stages
2 active programmes with forecast fields
Latest sourced update
Lophora Announces Positive Phase 1 Topline Results for LPH-5
Jun 10, 2026 - Press release - Lophora - LPH-5
Next known catalyst
preclinical-data
Q1 2027 - LPH-48 / LPH-48 Preclinical Programme - Confidence: 40%
7 sources0 pipeline-linked trials0 pipeline-linked papers1 Phase I1 Preclinical
Development Programmes
2LPH-5
Phase I
Treatment-resistant depression
Programme Tracker
Treatment-Resistant Depression (TRD)
Primary: EU (EMA)
Phase IActive
Forecast
Phase II started
Lophora dosed first subjects in Phase 1 in May 2025 and reported positive Phase 1 topline results for LPH-5 on June 10, 2026; the company now describes LPH-5 as entering Phase Ib.
Milestones
Phase I started
CompletedActual: May 1, 2025
First subjects dosed in Phase I SAD/MAD trial (EudraCT 2023-000463-32); trial site: Biotrial, Rennes, France
Why it matters: LPH-5 is the first 5-HT2A agonist NCE from a Scandinavian spinout to enter human trials. The EU CTA plus ANSM (French) approval validates LPH-5's preclinical safety package. SAD/MAD design in healthy volunteers will establish dose range and PK/PD for patient trials.
Watch next: Phase I topline safety and PK/PD data expected Q4 2025; IND filing for US Phase II
Funding milestone
CompletedActual: Jan 1, 2025
$3M financing closed (BioInnovation Institute, Innovation Fund Denmark, EIFO)
Why it matters: LPH-5 is a next-generation 5-HT2A agonist NCE engineered for selectivity — a novel psychedelic-inspired compound with composition-of-matter patents in US, EU, China, Japan. The $3M financing enables Phase I completion. BII is a Novo Nordisk Foundation subsidiary, adding credibility to the programme.
Recorded Events
May 1, 2025: Phase I started
Jan 1, 2025: Funding milestone
Evidence Links
ClinicalTrials.gov NCT06722820 - Study to Evaluate LPH-5
clinical-trial-registry - ClinicalTrials.gov - Dec 9, 2024 - Verified
Registry record for the Phase 1 healthy-volunteer study of LPH-5.
Lophora Receives EMA Approval to Initiate Phase I Trial for LPH-5
Press release - Lophora - Sep 17, 2024 - Verified
Company announcement says EMA approval was received for a first-in-man Phase 1 study of LPH-5.
Lophora Announces First Subjects Dosed in Phase 1 LPH-5 Trial
Press release - Lophora - May 28, 2025 - Verified
Company reported first subjects dosed in the Phase 1 LPH-5 study at Biotrial in Rennes, France.
Lophora Announces Positive Phase 1 Topline Results for LPH-5
Press release - Lophora - Jun 10, 2026 - Verified
Lophora news page reports positive Phase 1 topline results for LPH-5 on June 10, 2026.
Lophora receives additional funding to complete preclinical development of LPH-5
Press release - Lophora - Mar 2, 2021 - Verified
Company release reports US$0.9M from the Danish Growth Fund and a US$0.7M InnoBooster grant, following initial BioInnovation Institute investment.
LPH-48
Preclinical
CNS / neuropsychiatric disorders
Programme Tracker
Major Depressive Disorder (MDD)
Primary: EU (EMA)
Pre-clinicalActive
Forecast
preclinical-data - Likely: Q1 2027
LPH-48 remains a preclinical fast-follower to LPH-5, described by Lophora as a short-duration candidate with similar primary pharmacology. Lophora reported positive Phase 1 topline results for lead candidate LPH-5 on 2026-06-10, supporting continued platform development and Phase Ib entry for LPH-5.
Milestones
Pre-clinical started
ongoingWhy it matters: LPH-48 is a second NCE in Lophora's proprietary 5-HT2A agonist series, designed with an optimised profile relative to LPH-5. A two-asset pipeline reduces single-compound risk and provides backup if LPH-5 hits unexpected safety or PK issues in Phase I.
Watch next: Lead compound selection and IND-enabling study initiation
Evidence Links
Lophora Science and Pipeline - LPH-48
company-website - Lophora - Oct 24, 2025 - Verified
Pipeline page describes LPH-48 as a fast-follower short-duration therapeutic with similar primary pharmacology to LPH-5.
Lophora CTA Application Notes LPH-48 Fast-Follower Candidate
Press release - Lophora - May 31, 2024 - Verified
CTA announcement describes LPH-48 as a shorter-acting direct analogue and fast-follower to LPH-5.
Lophora positive Phase 1 topline results for LPH-5 platform lead
Press release - Lophora - Jun 10, 2026 - Verified
Platform-adjacent source for LPH-48: Lophora describes LPH-48 as a short-duration fast-follower to LPH-5 with similar primary pharmacology.
Similar Developers
Reference points selected from shared pipeline stage, indications, compounds, regulatory pathways, and evidence footprint.
Neurala Biosciences
Phase I2 active candidates
same indication: Major Depressive Disorder (MDD)Phase I peer2 overlapping stagessimilar active pipeline size
Seaport Therapeutics
Phase II3 active candidates
2 shared indications2 overlapping stagessimilar active pipeline sizeboth have forecast coverage
Arcadia Medicine
Phase I3 active candidates
same indication: Major Depressive Disorder (MDD)Phase I peer2 overlapping stagessimilar active pipeline size
Quick Facts
- Type
- Private Biotech
- Founded
- 2018
- Lead Stage
- Phase I
- Website
- Visit